Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Comparison of plasma and … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.

Artikel i vetenskaplig tidskrift
Författare Pierre de Flon
Katarina Laurell
Peter Sundström
Kaj Blennow
Lars Söderström
Henrik Zetterberg
Publicerad i Acta neurologica Scandinavica
Volym 139
Nummer/häfte 5
Sidor 462-468
ISSN 1600-0404
Publiceringsår 2019
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
Sidor 462-468
Språk en
Länkar dx.doi.org/10.1111/ane.13078
www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Biomarkers, analysis, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunologic Factors, therapeutic use, Male, Middle Aged, Multiple Sclerosis, Relapsing-Remitting, drug therapy, metabolism, Neurofilament Proteins, analysis, metabolism, Rituximab, therapeutic use
Ämneskategorier Neurokemi

Sammanfattning

The main objective of this study was to evaluate the axonal component neurofilament light protein (NFL) in plasma and cerebrospinal fluid (CSF) as an outcome measure in a clinical trial on disease-modifying treatments in multiple sclerosis.Seventy-five patients with clinically stable relapsing-remitting multiple sclerosis (RRMS) participating in the clinical trial "Switch-To RItuXimab in MS" (STRIX-MS) were switched to rituximab from first-line injectable therapy and then followed up for 2 years. Thirty patients from the extension trial (STRIX-MS extension), accepting repeated lumbar punctures, were followed up for an additional 3 years. Plasma and CSF samples were collected yearly during the follow-up. NFL concentration in plasma was measured by an in-house NF-light assay on the Simoa platform with a Homebrew kit. NFL concentration in CSF was measured by sandwich ELISA.The mean levels of NFL, in both CSF and plasma, were low. The reduction of CSF-NFL was 25% during the first year of follow-up (from a mean of 471 [SD 393] to 354 [SD 174] pg/mL; P = 0.006) and was statistically significant. The corresponding reduction in plasma NFL was 18% (from 9.73 [SD 7.04] to 7.94 [SD 3.10] pg/mL; P = 0.055) and did not reach statistical significance.This study indicates that NFL in plasma is less sensitive as an endpoint in group comparisons than NFL in CSF. Given that plasma NFL is far easier to access, it is a promising and awaited method but further studies are needed to optimize the use in clinical trials.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?